multiple sclerosis

Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression: Insights from the BENEFIT Study

By MedXY 08/20/2025

Higher baseline serum alpha-linolenic acid levels predict reduced multiple sclerosis activity, relapses, and disability progression up to 11 years post clinical onset in a large prospective study.

Clinical Updates Wellness & Lifestyle

Therapeutic Strategies for Disease-Modifying Therapy Management in Pregnant Women With Multiple Sclerosis: Relapse Risk and Clinical Implications

By MedXY 08/04/2025

Managing disease-modifying therapies (DMTs) during pregnancy in women with multiple sclerosis significantly affects relapse risk, with anti-CD20 strategies demonstrating superior protection compared to other approaches.

Clinical Updates Medical News

Fenebrutinib in Relapsing Multiple Sclerosis: New Evidence from the FENopta Phase 2 Trial

By MedXY 08/02/2025

Fenebrutinib, a selective BTK inhibitor, demonstrated significant reduction in new brain lesions and low relapse rates in relapsing multiple sclerosis, with a favorable safety profile in the FENopta phase 2 trial.

Clinical Updates Wellness & Lifestyle

Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials

By MedXY 08/02/2025

Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.